Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study
Heather J McElroy, Stuart K Roberts, Alex J Thompson, Peter W Angus, Sarah Jane McKenna, Emma Warren, Sharon Musgrave
Journal of Medical Economics | TAYLOR & FRANCIS LTD | Published : 2017
OBJECTIVE: To evaluate medical resource utilization (MRU) and associated costs among Australian patients with genotype 1 chronic hepatitis C (GT1 CHC), including both untreated patients and those receiving treatment with first-generation protease inhibitor-based regimens (telaprevir, boceprevir with pegylated interferon and ribavirin). METHODS: Medical records were reviewed for a stratified random sample of GT1 CHC patients first attending two liver clinics between 2011-2013 (principal population; PP), supplemented by all GT1 CHC patients attending one transplant clinic in the same period (transplant population; TP). CHC-related MRU and associated costs are reported for the PP by treatment s..View full abstract
This research was sponsored by AbbVie Pty Ltd.